X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Natco Pharma with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 NATCO PHARMA   MYLAN
EQUITY SHARE DATA
    NATCO PHARMA
Mar-18
MYLAN
Dec-14
NATCO PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs1,0804,285-   
Low Rs6713,019-   
Sales per share (Unadj.) Rs592.11,466.8-  
Earnings per share (Unadj.) Rs188.4176.7-  
Cash flow per share (Unadj.) Rs206.3284.4-  
Dividends per share (Unadj.) Rs8.250-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs833.6729.1-  
Shares outstanding (eoy) m36.90378.37-   
Bonus/Rights/Conversions ISOI-  
Price / Sales ratio x1.52.5 59.4%   
Avg P/E ratio x4.620.7 22.5%  
P/CF ratio (eoy) x4.212.8 33.1%  
Price / Book Value ratio x1.15.0 21.0%  
Dividend payout %4.40-   
Avg Mkt Cap Rs m32,3111,381,812 2.3%   
No. of employees `0004.825.0 19.3%   
Total wages/salary Rs m3,2560-   
Avg. sales/employee Rs Th4,522.522,199.6 20.4%   
Avg. wages/employee Rs Th674.00-   
Avg. net profit/employee Rs Th1,439.02,674.3 53.8%   
INCOME DATA
Net Sales Rs m21,848554,991 3.9%  
Other income Rs m404-3,235 -12.5%   
Total revenues Rs m22,252551,756 4.0%   
Gross profit Rs m9,284138,029 6.7%  
Depreciation Rs m66240,762 1.6%   
Interest Rs m15423,939 0.6%   
Profit before tax Rs m8,87270,093 12.7%   
Minority Interest Rs m0-288 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,9202,947 65.1%   
Profit after tax Rs m6,95266,858 10.4%  
Gross profit margin %42.524.9 170.9%  
Effective tax rate %21.64.2 514.6%   
Net profit margin %31.812.0 264.1%  
BALANCE SHEET DATA
Current assets Rs m21,307487,910 4.4%   
Current liabilities Rs m5,920381,448 1.6%   
Net working cap to sales %70.419.2 367.1%  
Current ratio x3.61.3 281.4%  
Inventory Days Days7378 93.8%  
Debtors Days Days107107 99.3%  
Net fixed assets Rs m14,986128,396 11.7%   
Share capital Rs m36919,626 1.9%   
"Free" reserves Rs m30,3530-   
Net worth Rs m30,760275,885 11.1%   
Long term debt Rs m0412,145 0.0%   
Total assets Rs m37,1511,111,240 3.3%  
Interest coverage x58.63.9 1,492.1%   
Debt to equity ratio x01.5 0.0%  
Sales to assets ratio x0.60.5 117.8%   
Return on assets %19.18.2 234.1%  
Return on equity %22.624.2 93.3%  
Return on capital %29.313.6 215.4%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m7,3430-   
CASH FLOW
From Operations Rs m4,63672,954 6.4%  
From Investments Rs m-11,155-57,534 19.4%  
From Financial Activity Rs m6,509-19,223 -33.9%  
Net Cashflow Rs m-18-3,803 0.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 71.89 Rs / USD

Compare NATCO PHARMA With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare NATCO PHARMA With: LUPIN LTD  FULFORD INDIA  CIPLA  J.B.CHEMICALS  STRIDES PHARMA SCIENCE  



Today's Market

Sensex Ends 317 Points Higher; Realty and FMCG Stocks Witness Buying(Closing)

Indian share markets continued to trade on a positive note during closing hours of trade and ended the day on a strong note. Gains were largely seen in the realty sector and FMCG sector.

Related Views On News

NATCO PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 115.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 115.2% YoY). Sales on the other hand came in at Rs 5 bn (up 27.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Nov 19, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS